# A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU

Source: https://onco.cc/trials/nct07642024/  
OnCo record `nct07642024` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Izalontamab brengitecan, Osimertinib, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) is a phase 2/3 interventional study registered as NCT07642024 by Sichuan Baili Pharmaceutical Co., Ltd., with 90 participants planned, started 2026-07-24 and due to reach its primary completion in 2032-12. Interventions recorded: BL-B01D1, Osimertinib, Carboplatin, Pemetrexed, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07642024
- Phase: 2/3
- Setting: A Phase II/III Randomized Controlled Clinical Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07642024: https://clinicaltrials.gov/study/NCT07642024

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07642024.json